Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has announced its participation in two major upcoming healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has announced its participation in two major upcoming healthcare investor conferences. Management will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 6:00 PM ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 2:00 PM ET. Both presentations will be available for viewing through live and archived webcasts on the company's investor relations website at investor.myriad.com.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +7.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Correction: Time of BofA Conference
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences:
- The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.
- Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025.
Live and archived webcasts of all presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.